SPARK appointed as Nominated Adviser to ImmuPharma plc

SPARK Advisory Partners Limited (“SPARK”) is pleased to announce it has been appointed as Nominated Adviser to ImmuPharma plc.

ImmuPharma plc is a specialist drug discovery and development company headquartered in London and listed on the AIM market of the London Stock Exchange (LSE: IMM). Its research operations are in France. ImmuPharma is dedicated to the development of novel drugs, largely based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases characterised by high unmet medical need, low marketing costs and relatively low development costs.